摘要
Purpose: To explore the prognostic value of the plasma load of Epstein-Barr viral (EBV) DNA and the tumor response to neoadjuvant chemotherapy (NACT) in advanced-stage nasopharyngeal carcinoma (NPC). Patients and Methods: In all, 185 consecutive patients with stage III to IVb NPC treated with NACT followed by concurrent chemoradiation therapy (CCRT) were prospectively enrolled. The primary endpoint was progression-free survival (PFS), and the secondary endpoints included locoregional relapseefree survival (LRFS) and distant metastasisefree survival (DMFS). Results: EBV DNA was detected in 165 (89%) patients before treatment but was undetectable in 127 (69%) patients after NACT. Detectable EBV DNA levels after NACT were correlated with poor prognosis (3-year PFS 71.8% vs 85.2%, P = .008 and 3-year DMFS 82.5% vs 92.3%, P = .013). An unsatisfactory tumor response (stable disease or disease progression) after NACT was also correlated with poor clinical outcome (3-year PFS 71.1% vs 85.9%, P = .005 and 3-year LRFS 82.7% vs 93.5%, P = .012). Multivariate analysis showed that the EBV DNA level after NACT (hazard ratio [HR] 2.31, 95% CI 1.18-4.54, P = .015) and the tumor response to NACT (HR 2.84, 95% CI 1.42-5.67, P = .003) were both significant prognostic factors for PFS. Multivariate analysis also showed that EBV DNA after NACT was the only significant predictor of DMFS (HR 2.99, 95% CI 1.25-7.15, P = .014) and that tumor response to NACT was the only significant predictor of LRFS (HR 3.31, 95% CI 1.21-9.07, P = .020). Conclusion: Detectable EBV DNA levels and an unsatisfactory tumor response (stable disease or disease progression) after NACT serve as predictors of poor prognosis for patients with advanced-stage NPC. These findings will facilitate further risk stratification, early treatment modification, or both before CCRT.
学科与关键词
- Plasma Epstein-Barr Virus DNA Load After Induction Chemotherapy Predicts Outcome in Locoregionally Advanced Nasopharyngeal CarcinomaCheng-Long Huang; Zheng-Qiang Sun; Rui Guo; Xu Liu; Yan-Ping Mao; Hao Peng; Li Tian; Ai-Hua Lin; Li Li; Jian-Yong Shao; Ying Sun; Jun Ma; Ling-Long TangInternational Journal of Radiation Oncology Biology Physics, 2019, 104(2): 355-361.
- Circulating Epstein-Barr virus DNA level post induction chemotherapy contributes to prognostication in advanced-stage nasopharyngeal carcinomaChen, Fo-Ping; Luo, Ying-Shan; Chen, Kai; Li, Jun-Yun; Huo, Lan-Qing; Shi, Liu; Ou-Yang, Yi; Cao, Xin-Ping*European Journal of Cancer, 2021, 151: 63-71.
- Integrating pre- and post-treatment Plasma Epstein-Barr Virus DNA levels for better prognostic prediction of Nasopharyngeal CarcinomaLi, Wanxia; Yang, Chao; Lv, Zehong; Li, Junzheng; Li, Zonghua; Yuan, Xiaofei; Wu, Shuting; Yuan, Yue; Cui, Linchong; Lu, Juan*; Chen, Jing*; Zhao, Feipeng*American Journal of Cancer Research, 2021, 12(9): 2715-2722.被引 11
